chronic obstructive pulmonary disease. Other chronic obstructive pulmonary disease
Conditions
Interventions
Intervention 1: Intervention group: Receives Montelukast, manufactured by Zahravi Pharmaceutical Company, at a dose of one 10 mg oral tablet daily for two months. Intervention 2: Control group: Receiv
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients aged 40 to 70 years Diagnosed with moderate to severe COPD Clinically stable over the past three months No history of hospitalization in the past six months Signed written informed consent
Exclusion criteria
Exclusion criteria: Patients with advanced cardiovascular disease, including EF less than 40% Rheumatologc diseases Uncontrolled hypertension Progressive kidney disease with a glomerular filtration rate (GFR) less than 30 mL/min Hypersensitivity to Montelukast
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FEV1. Timepoint: One day before the intervention, and at two and four months after the start of the intervention. Method of measurement: Spirometer.;FVC. Timepoint: One day before the intervention, and at two and four months after the start of the intervention. Method of measurement: Spirometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| FEF25–75%. Timepoint: One day before the intervention, and at two and four months after the start of the intervention. Method of measurement: Spirometer.;FEV1/FVC ratio. Timepoint: One day before the intervention, and at two and four months after the start of the intervention. Method of measurement: Spirometer.;The number of exacerbation episodes. Timepoint: Two and four months after the start of the intervention. Method of measurement: History taking.;Clinical improvement in dyspnea. Timepoint: One day before the intervention, and at two and four months after the start of the intervention. Method of measurement: The modified Medical Research Council questionnaire.;Clinical improvement in dyspnea. Timepoint: One day before the intervention, and at two and four months after the start of the intervention. Method of measurement: The chronic obstructive pulmonary disease assessment test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Hajiani
Ahvaz University of Medical Sciences
Outcome results
None listed